Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...

Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023 ...

In a public health breakthrough, U.S. obesity rates have decreased for the first time in more than a decade, with new weight ...

KOCHI: Obesity has grown into a global epidemic, affecting nearly every corner of the world. According to 2022 data from the ...

Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA ...

On its own, obesity can cause acute ailments, including breathlessness and back pain. Worse, it often leads to other chronic ...

A new study reveals that modulating endocannabinoids in the brain can reduce food intake and boost physical activity, ...

If coverage is structured properly, it could greatly help our country's chronic disease and obesity epidemics. But Donald Trump's Food and Drug Administration (FDA) will also need to ensure the drugs ...

A new study published in the JAMA Health Forum found that obesity rates dropped from 46% in 2022 to 45.6% in 2023. The study ...

Endocannabinoids in the brain play a key role in food intake and energy use. Modulating the action of these molecules could help fight obesity, say researchers.

The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I ...

The obesity rate among US adults declined in 2023 for the first time in over a decade, as per a study published in the JAMA ...